39 results about "CYP1A2" patented technology

The invention discloses SNP rs762551 of a CYP1A2 gene and application thereof in relevant drug metabolism activity detection, and also provides a method for prejudging drug metabolism activity. The method comprises the steps of detecting whether the cytochrome oxidase P4501A2 gene (CYP1A2) and a transcript of a human individual have variation or not compared with a normal cytochrome oxidase P4501A2 gene and a normal transcript, and if so, showing that the drug metabolism activity of the individual is different from common or normal people, for the individual. The invention also discloses a corresponding detection kit used for prejudging the drug metabolism activity of the individual.

The invention belongs to the technical field of molecular biological gene polymorphism detection, and in particular relates to a kit and a method for genotyping detection. The kit consists of a firstprimer pair and a first molecular beacon probe for ADH1B gene rs1229984 site, a second primer pair and a second molecular beacon probe for ALDH2 gene rs671 site, a third primer pair and a third molecular beacon probe for CYP1A2 gene rs762551 site, and a fourth primer pair and a fourth molecular beacon probe for TMPRSS6 gene rs855791 site. With the application of the kit provided by the invention,four genotypes corresponding to the genes and corresponding metabolic absorption types can be rapidly and conveniently detected.

The teachings provided herein generally relate to compositions comprising rutaecarpine derivatives that activates CYP1A2 through enzyme induction. The uses for such a derivative can include removing caffeine from a subject, improving sleep, treating insomnia, treating caffeine toxicity, treating caffeine addiction and withdrawal symptoms, and the like. Caffeine is just one example of a substrate that can be removed using the derivatives taught herein, and other examples, including theophylline, are provided herein.

The invention relates to a novel cocktail probe medicament combination comprising caffeine, metoprolol, chlorzoxazone, tolbutamide and midazolam. The influence of hepatic ischemia preconditioning and hepatic ischemia-reperfu-sion injury on medicament metabolism activity of rat CYP1A2, CYP2C9, CYP2E1, CYP2D6, and CYP3A4 in vivo is evaluated through the change of pharmacokinetics parameters of the combination.

The invention discloses a gene polymorphism detection kit for guiding psychiatric medication. The kit comprises a specific primer group and a fluorescent probe group, wherein the specific primer group and the fluorescent probe group are used for detecting the rs1065852 site of a CYP2D6 gene, the rs1414334 site of an HTR2C gene, the rs1800497 site of an ANKK1 gene, the rs762551 site of a CYP1A2 gene, the rs489693 site of an MC4R gene and the rs1799978 site of a DRD2 gene. According to the invention, the primer group and the fluorescent probe group are utilized, and the template DNA is specifically amplified by using a fluorescent PCR amplification technology, so that the polymorphism of a plurality of sites of a plurality of genes related to psychotropic drugs can be accurately detected at the same time; ARMS primer design is adopted, mismatched bases are introduced, the specificity of primer amplification is improved, the sensitivity is high, and accurate genotyping can be conducted on human template DNA at the lowest DNA initial amount of 10 ng; the detection speed is high and the efficiency is high: the PCR reaction only needs less than 1 hour to complete the amplification reaction, the cost is lower, the required reagent consumables are all clinically common reagents, the cost is lower, and the clinical popularization is convenient.

The invention belongs to the field of gene diagnosis, and discloses a real-time fluorescence PCR method of detecting a rs762551 site of a CYP1A2 gene, and a primer-and-probe combination of the real-time fluorescence PCR method. A sequence of one forward primer FpG is 5'-GGTGAGCTCTGTGGGGC-3', a sequence of the other forward primer FpG is 5'-GGTGAGCTCTGTGGGGA-3', a sequence of a reverse primer Rp is5'-GCTGAGGGTTGAGATGGAGAC-3', and a sequence of a probe Probe is 5'-Cy5-ACGCATGGTAGATGGAGCTTAG-BHQ2-3'. After a PCR is completed, results can be analyzed through whether or not an amplification curveexists and in combination with a Ct value. The real-time fluorescence PCR method of detecting the rs762551 site of the CYP1A2 gene is applied to polymorphism detection of the rs762551 site, and has the advantages of being easy to operate, high in resolution, free of pollution, and high in throughput.

the invention discloses a gene CYP1A2 genotypic and detecting method and relative genotypic agent box and application, which provides molecular criterion for metabolic dose.

The present invention relates to a preparation method of CYP1A2 polypeptide and antihuman CYP1A2 polypeptide antibody. The amino acid sequence of CYP1A2 polypeptide is GRERRPRLSDRPQLP. The preparation method of antihuman CYP1A2 polypeptid antibody includes the following steps: (1) analysis of CYP1A2 antigen epitope; (2) synthesis of CYP1A2 polypeptide; (3) CYP1A2 polypeptide and carrier protein crosslinking; (4) preparing rabbit anti-CYP1A2 polypeptide antibody; and (5) collecting and separating to obtain serum containing antibody, purifying antibody so as to obtain anti-human CYP1A2 polypeptide antibody.

The invention belongs to the technical field of biological medicine, and discloses a construction method of a CYP enzyme humanized rat animal model for drug metabolism research and application of the CYP enzyme humanized rat animal model. The construction method comprises genotype identification, humanized gene expression identification and humanized gene function verification. The method comprises the following steps of firstly, constructing a CYP enzyme humanized rat by utilizing a CRISPR system, including selection of a gene editing target spot, in-vitro synthesis and transcription of sgRNA and Cas9 mRNA, construction of a homologous recombination template, preparation of a pseudopregnant female rat, in-vitro microinjection and transplantation of a single-cell embryo and reproduction of the rat, finally obtaining a homozygote CYP gene humanized rat, then performing CYP enzyme expression detection on the homozygous humanized rat from a protein level, and performing metabolic function verification to prove that the CYP humanized rat is successfully constructed. The CYP1A2 humanized rat has metabolic characteristics more similar to those of people, the species difference of CYP1A2 mediated drug metabolism between the rat and the people is eliminated, and a new rat animal model is provided for research on CYP mediated drug metabolism.

The invention relates to an absolute quantitative method for biomass spectra of CYP450 enzyme hypotypes, and belongs to the technical field of proteomics. In the method, on the basis of liquid chromatography (LC) / mass spectrometry (MS) / MS, the absolute quantification of four CYP450 enzyme hypotypes, namely CYP1A2, CYP2B6, CYP3A4 and CYP3A5 in systems such as liver microsome and the like is realized simultaneously by a strategy that CYP450 generates specific peptide quantitative enzymes by pancreatic enzyme hydrolysis. The method mainly comprises the following steps of: preprocessing a proteinsample, preparing a standard curve, measuring the protein sample and preparing a quality control sample. The absolute quantitative method has excellent linear relations, is high in accuracy and repeatability, is sensitive, precise and reliable, and can be used for medicinal metabolism and the evaluation of the mutual effect of medicaments.

The invention relates to a novel cocktail probe medicament combination comprising caffeine, metoprolol, chlorzoxazone, tolbutamide and midazolam. The influence of hepatic ischemia preconditioning and hepatic ischemia-reperfu-sion injury on medicament metabolism activity of rat CYP1A2, CYP2C9, CYP2E1, CYP2D6, and CYP3A4 in vivo is evaluated through the change of pharmacokinetics parameters of the combination.

The invention discloses a method for predicting inhibition concentration of a cytochrome P450 enzyme CYP1A2 inhibitor by utilizing simplified partial least squares. The method comprises the steps of: 1) collecting, processing and optimizing sample sets; 2) constructing molecular descriptors of the inhibitor; 3) preliminarily screening molecular descriptors of the inhibitor; 4) scaling data sets of molecular descriptors of the inhibitor again; 5), dividing data sets of molecular descriptors of the inhibitor; 6), setting up a QSAR model; and 7) predicting inhibition concentration of the cytochrome P450 enzyme CYP1A2 inhibitor.The method utilizes the method of partial least squares (PLS) to further estimate and simplify constituents of partial least squares (PLS) in the presence of serious multiple correlations of independent variables on the basis of regression modeling and uses the simplified method of partial least squares (SIMPLS) to precisely predict inhibition concentration of the cytochrome P450 inhibitor.